medbioМедико-биологические проблемы жизнедеятельностиMedical and Biological Problems of Life Activity2074-2088Республиканский научно-практический центр радиационной медицины и экологии человекаmedbio-217Research ArticleКЛИНИЧЕСКАЯ МЕДИЦИНАCLINICAL MEDICINEЛабораторные и клинические признаки прогрессии моноклональной гаммапатии неуточненного генеза и множественной миеломыLaboratory and clinical signs of progression monoclonal gammapathy of undetermined significance and multiple myeloma in patientsКозичЖ. М.KozichZh. .noemail@neicon.ruМартинковВ. Н.MartinkovV. .noemail@neicon.ruЗиновкинД. А.ZinovkinD. .noemail@neicon.ruСилинА. Е.SilinA. .noemail@neicon.ruЖандаровМ. Ю.ZhandarovM. .noemail@neicon.ruПугачеваЖ. Н.PugachevaZh. .noemail@neicon.ruКоротаеваЛ. Е.KorotaevaL. .noemail@neicon.ruСмирноваЛ. А.SmirnovaL. .noemail@neicon.ruГУ «РНПЦ радиационной медицины и экологии человека»Russian FederationУО «Гомельский государственный медицинский университет»Russian FederationУО «Белорусская медицинская академия последипломного образования»Russian Federation201902032023029098Copyright © Козич Ж.М., Мартинков В.Н., Зиновкин Д.А., Силин А.Е., Жандаров М.Ю., Пугачева Ж.Н., Коротаева Л.Е., Смирнова Л.А., 20232023Козич Ж.М., Мартинков В.Н., Зиновкин Д.А., Силин А.Е., Жандаров М.Ю., Пугачева Ж.Н., Коротаева Л.Е., Смирнова Л.А.Kozich Z..., Martinkov V..., Zinovkin D..., Silin A..., Zhandarov M..., Pugacheva Z..., Korotaeva L..., Smirnova L...Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://medbio.ejournal.by/jour/article/view/217

Множественная миелома (ММ) относится к опухолям лимфоидного происхождения, характеризуется моноклональной пролиферацией плазматических клеток в костном мозге. В своем развитии ММ проходит стадию моноклональной гаммапатии неуточненного генеза (МГНГ). Одной из важных целей исследования ММ является ее диагностика на ранних этапах с возможным выявлением факторов прогноза прогрессии. Определение прогностических факторов на основе исследования иммунофенотипических маркеров, микроокружения клеток костного мозга будет способствовать распределению пациентов по группам риска и своевременному началу специфической терапии. В данной статье мы проанализировали результаты клинико-лабораторного, иммунофенотипического, цитогенетического, молекулярно-генетического и гистологического методов исследования пациентов на ранних этапах развития заболевания.

Multiple myeloma (MM) is one of the dyscrasia of lymphoid origin, the terminal differentiation of B-lymphocytes - plasma cells. In its development, MM undergoes a stage of monoclonal gammopathy of undetermined significance (MGUS) and smoldering or asymptomatic myeloma. One of the important aims of the diagnosis of multiple myeloma (MM) is its diagnosis in the early stages, with the possible determination of prognostic factors of progression. Determination of prognostic factors based on a study of immunophenotypic markers of progression, the microenvironment of bone marrow cells, may help to initially identify patients of risk groups for progression, which is important in terms of time of starting specific therapy. In this article, we have analyzed clinical and laboratory data, data on immunophenotypic, cytogenetic, molecular genetic and histological methods for examining patients in the early stages of development - MGUS and at newly diagnosed MM.

моноклональная гаммапатия неуточненного генезамножественная миеломаметоды диагностикифакторы риска прогрессииmonoclonal gammopathy of undetermined significancemultiple myelomarisk factors for progressionReferencesAgarwal, A. Monoclonal Gammopathy of Undetermined Significance and Smoldering Multiple Myeloma: A Review of the Current Understanding of Epidemiology, Biology, Risk Stratification, and Management of Myeloma Precursor Disease / A. Agarwal, I.M. Ghobrial // Clin. Cancer Res. - 2013. - Vol. 19, № 5. - P. 985-994.Agarwal, A. Monoclonal Gammopathy of Undetermined Significance and Smoldering Multiple Myeloma: A Review of the Current Understanding of Epidemiology, Biology, Risk Stratification, and Management of Myeloma Precursor Disease / A. Agarwal, I.M. Ghobrial // Clin. Cancer Res. - 2013. - Vol. 19, № 5. - P. 985-994.Prevalence of monoclonal gammopathy of undetermined significance / R.A. Kyle [et al.] // N. Engl. J. Med. - 2006. - Vol. 354, № 13. - P. 1362-1369.Prevalence of monoclonal gammopathy of undetermined significance / R.A. Kyle [et al.] // N. Engl. J. Med. - 2006. - Vol. 354, № 13. - P. 1362-1369.Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management / R.A. Kyle [et al.] // Leukemia. - 2010. - Vol. 24, № 6. - P. 1121-1127.Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management / R.A. Kyle [et al.] // Leukemia. - 2010. - Vol. 24, № 6. - P. 1121-1127.Zingone, A. Pathogenesis of Monoclonal Gammopathy of Undetermined Significance and Progression to Multiple Myeloma / A. Zingone, W.M. Kuehl // Semin. Hematol. - 2011. - Vol. 48, № 1. - P. 4-12.Zingone, A. Pathogenesis of Monoclonal Gammopathy of Undetermined Significance and Progression to Multiple Myeloma / A. Zingone, W.M. Kuehl // Semin. Hematol. - 2011. - Vol. 48, № 1. - P. 4-12.Rajkumar, S.V. Multiple Myeloma: Diagnosis and Treatment / S.V. Rajkumar, S. Kumar // Mayo Clin. Proc. - 2016. - Vol. 91, № 1. - P. 101-119.Rajkumar, S.V. Multiple Myeloma: Diagnosis and Treatment / S.V. Rajkumar, S. Kumar // Mayo Clin. Proc. - 2016. - Vol. 91, № 1. - P. 101-119.Utility of flow cytometry immunophenotyping in multiple myeloma and other clonal plasma cell-related disorders / B. Paiva [et al.] // Cytometry B. Clin. Cytom. - 2010. - Vol. 78, № 4. - P. 239-252.Utility of flow cytometry immunophenotyping in multiple myeloma and other clonal plasma cell-related disorders / B. Paiva [et al.] // Cytometry B. Clin. Cytom. - 2010. - Vol. 78, № 4. - P. 239-252.The Assessment of CD56 and CD117 Expressions at the Time of the Diagnosis in Multiple Myeloma Patientsple Myeloma Patients / F. Ceran [et al.] // Turkish J. Hematol. - 2017. - Vol. 34, № 3. - P. 226.The Assessment of CD56 and CD117 Expressions at the Time of the Diagnosis in Multiple Myeloma Patientsple Myeloma Patients / F. Ceran [et al.] // Turkish J. Hematol. - 2017. - Vol. 34, № 3. - P. 226.Prevalence of myeloma precursor state monoclonal gammopathy of undetermined significance in 12372 individuals 10-49 years old: a population-based study from the National Health and Nutrition Examination Survey / O. Landgren [et al.] // Blood Cancer J. - 2017. - Vol. 7, № 10. - P. e618-e618.Prevalence of myeloma precursor state monoclonal gammopathy of undetermined significance in 12372 individuals 10-49 years old: a population-based study from the National Health and Nutrition Examination Survey / O. Landgren [et al.] // Blood Cancer J. - 2017. - Vol. 7, № 10. - P. e618-e618.New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells / E. Pérez-Persona [et al.] // Blood. - 2007. - Vol. 110, № 7. - P. 2586-2592.New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells / E. Pérez-Persona [et al.] // Blood. - 2007. - Vol. 110, № 7. - P. 2586-2592.Widespread Genetic Heterogeneity in Multiple Myeloma: Implications for Targeted Therapy /j.G. Lohr [et al.] // Cancer Cell. - 2014. - Vol. 25, № 1. - P. 91-101.Widespread Genetic Heterogeneity in Multiple Myeloma: Implications for Targeted Therapy /j.G. Lohr [et al.] // Cancer Cell. - 2014. - Vol. 25, № 1. - P. 91-101.High incidence of N and K-Ras activating mutations in multiple myeloma and primary plasma cell leukemia at diagnosis / S. Bezieau [et al.] // Hum. Mutat. - 2001. - Vol. 18, № 3. - P. 212-224.High incidence of N and K-Ras activating mutations in multiple myeloma and primary plasma cell leukemia at diagnosis / S. Bezieau [et al.] // Hum. Mutat. - 2001. - Vol. 18, № 3. - P. 212-224.Conventional diagnostics in multiple myeloma /j.F. San Miguel [et al.] // Eur. J. Cancer. - 2006. - Vol. 42, № 11. - P. 1510- 1519.Conventional diagnostics in multiple myeloma /j.F. San Miguel [et al.] // Eur. J. Cancer. - 2006. - Vol. 42, № 11. - P. 1510- 1519.

The authors declare that there are no conflicts of interest present.